May 18, 2021
A key Japanese health ministry panel will review whether to back approval of Daiichi Sankyo’s sakigake -designated oncolytic virus G47∆ (teserpaturev) on May 24 for an indication of malignant glioma. A number of companies are developing oncolytic viruses, and teserpaturev...read more